Berger Montague Shareholder Susan Schneider Thomas to Speak at The Future of Qui Tam & False Claims Act: What’s In and Out of 2017? LIVE Webcast
Berger Montague Shareholder Susan Schneider Thomas will speak at The Future of Qui Tam & False Claims Act: What’s In and Out of 2017? LIVE Webcast on May 18, 2017. The webcast is sponsored by The Knowledge Group and will stream live on their website from 10 a.m. to 11:30 a.m. EST on May 18.
Ms. Thomas will join a panel of key thought leaders to provide an overview to help attendees understand the critical elements of qui tam and the False Claims Act and the potential changes they might undergo in the succeeding years. Speakers will also provide an in-depth discussion of the False Claims Act and give significant insights on the potential impacts of the current administration.
Some of the major topics that will be covered during this webcast are:
- Recent developments in qui tam litigation
- Impact of the Supreme Court’s decision in Escobar
- Defensive techniques using heightened materiality standard
- Plaintiff perspective on the post-Escobar landscape
- False Claims Act enforcement under President Trump
- What’s in and out for 2017
Click here to learn more about the webcast and register.
Ms. Thomas is a shareholder in the Consumer Fraud and Whistleblower/Qui Tam practice groups at Berger Montague. She concentrates her practice on qui tam litigation and has substantial complex litigation experience.
Ms. Thomas has had major responsibilities in many securities and consumer fraud class actions, including In re CryoLife Securities Litigation, C.A. No. 1:02-CV-1868 BBM (N.D.Ga.), which settled in 2005 for $23.25 million, and In re First Alliance Mortgage Co., Civ. No. SACV 00-964 (C.D.Cal.), a deceptive mortgage lending action which settled for over $80 million in cooperation with the FTC.
More recently, Ms. Thomas has concentrated her practice in the area of healthcare qui tam litigation. As co-counsel for a team of whistleblowers, she worked extensively with the U.S. Department of Justice and various State Attorney General offices in the prosecution of False Claims Act cases against pharmaceutical manufacturers that recovered more than $2 billion for Medicare and Medicaid programs and over $350 million for the whistleblowers. She has investigated or is litigating False Claims Act cases involving defense contractors, off-label marketing by drug and medical device companies, federal grant fraud, upcoding and other billing issues by healthcare providers, drug pricing issues and fraud in connection with for-profit colleges and student loan programs.